Appointment of new CEO

Fulcrum Pharma PLC
10 March 2008



10th March 2008

                               FULCRUM PHARMA PLC
                                ('the Company')

                             Appointment of new CEO


Further to the announcement made on 10 January 2008, Fulcrum Pharma plc (AIM:
FUL), the drug development and regulatory services company, announces that it
has today appointed Dr Frank Armstrong as its new Chief Executive Officer as
from 1st April 2008.

Dr. Armstrong has more than 20 years' experience at major pharmaceutical and
leading biotechnology companies where he has been integral in bringing new
pharmaceutical products to the market.

Most recently, Dr. Armstrong was President and Chief Executive Office of CuraGen
Corporation, a NASDAQ listed biopharmaceutical company, from March 2006 until
September 2007. Prior to CuraGen, Dr. Armstrong was CEO of Bioaccelerate
Holdings Inc., Provensis Ltd. and Phoqus Pharmaceuticals plc. From 1998 to 2001,
Dr. Armstrong was Executive Vice President and Head of Worldwide Product
Development for Bayer AG, Germany, and from 1985 to 1998 served in various roles
with ICI Pharmaceuticals, then Zeneca in the UK and USA where his final position
was Senior Vice President of the Medical Research and Communications Group.

Dr. Armstrong received his MBChB from the University of Edinburgh and became a
member of the Royal College of Physicians in 1984. He was elected a Fellow of
the Royal College of Physicians, Edinburgh, in 1993 and elected a Fellow of the
Faculty of Pharmaceutical Physicians in 1994.

Sir Charles George, Chairman of Fulcrum Pharma, said:

'The Board is delighted to welcome Dr Armstrong as Fulcrum's new CEO. Frank
brings a wealth of leadership experience from a wide range of companies within
our industry that will be invaluable in guiding Fulcrum in the next stages of
our growth.

'I also wish to thank Dr Jon Court for having steered Fulcrum to where we are
today as its CEO and welcome him to his new role as Director of Strategic
Business Development.'

For further information, please contact:

Fulcrum Pharma PLC
Geoffrey Smith, Finance Director                   Tel: [phone]

Seymour Pierce
Jonathan Wright                                    Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that
provides global expertise to achieve drug development and regulatory approval
milestones. Fulcrum Pharma offers immediate access to a highly credible,
integrated development team that provides strategic and operational leadership
required to ensure that new drugs move smoothly from discovery research to
product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having
successfully floated in March 2000.

Notes:

Dr. Frank Murdoch Armstrong, age 51, is currently a director of CuraGen
Corporation. Within the past five years, he has been a director of the following
companies:

454 Life Sciences Corporation
Bioaccelerate Holdings, Inc.
Provensis Limited
Phoqus Pharmaceuticals (UK) Limited
Phoqus Pharmaceuticals plc
Avidex Limited (now named Medigene Limited)




                      This information is provided by RNS
            The company news service from the London Stock Exchange